RxDoctor Payments Data

Jeffrey Craig, MD

Internal Medicine · Owasso, OKNPI 1497982052

Payments from drug & device makers

$2,282in general payments, 2019–2025

Across 142 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$365
  • Amgen$325
  • Lilly USA, LLC$277
  • Pfizer$203
  • Merck$199
  • AbbVie$161
  • plus $752 from 17 others

What the payments were for

  • Food & beverage$2,26099%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,282 in reported general payments places this provider in the 75th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$128,107
Medicare patients
217
Services billed
2,275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban149$170,522
MounjaroTirzepatide109$138,850
OzempicSemaglutide77$95,195
FarxigaDapagliflozin Propanediol53$72,127
TrulicityDulaglutide57$63,139
XareltoRivaroxaban45$50,414
JardianceEmpagliflozin30$28,910
EntrestoSacubitril/Valsartan20$23,183
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$15,941
JanuviaSitagliptin Phosphate13$15,587
Repatha SureclickEvolocumab17$13,257
Atorvastatin Calcium685$9,494
Aimovig AutoinjectorErenumab-Aooe12$9,242
MyrbetriqMirabegron15$8,698
Tresiba Flextouch U-100Insulin Degludec11$8,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$277$201,989166 claims
PfizerEliquis$203$170,522149 claims
Novo NordiskOzempic$365$95,19577 claims
AstraZenecaFarxiga$91$72,12753 claims
Johnson & JohnsonXarelto$50$50,41445 claims
Boehringer IngelheimJardiance$95$28,91030 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$95$27,95846 claims
NovartisEntresto$26$23,18320 claims
MerckJanuvia$199$15,58713 claims
AbbVieSynthroid$161$2,10628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Owasso

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →